Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday’s Mid-Day Session
Gainers
InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares jumped 178.5% to $12.45 after gaining over 12% on Wednesday.
Timber Pharmaceuticals Granted U.S. Patent Titled ‘ISOTRETINOIN FORMULATIONS AND USES AND METHODS THEREOF (FOR THE TREATMENT OF ICHTHYOSIS AND OTHER SKIN CONDITIONS)’
https://patentcenter.uspto.gov/#!/applications/16875710/ifw/docs
62 Biggest Movers From Yesterday
Gainers
Missfresh Limited (NASDAQ: MF) jumped 51.1% to close at $0.2450 on Wednesday.
Timber Pharmaceuticals Q1 EPS $(0.05), Same YoY, Sales $83.18K Up From $40.73K YoY
Timber Pharmaceuticals (AMEX:TMBR) reported quarterly losses of $(0.05) per share. This is unchanged from the same period last year. The company reported $83.18 thousand in sales this quarter. This is a 104.20 percent
HC Wainwright & Co. Maintains Buy on Timber Pharmaceuticals, Lowers Price Target to $1.5
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Timber Pharmaceuticals (AMEX:TMBR) with a Buy and lowers the price target from $2 to $1.5.
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
Here's a roundup of top developments in the biotech space over the last 24 hours:
64 Biggest Movers From Friday
Gainers
Clever Leaves Holdings Inc. (NASDAQ: CLVR) shares surged 143% to settle at $3.84 on Friday after the company reported better-than-expected Q4 sales results and reaffirmed FY22 guidance.
Timber Pharmaceuticals Announces End-of-Phase 2 Meeting With FDA For TMB-001 In Moderate To Severe Congenital Ichthyosis; Co. Plans To Initiate Phase 3 Study In Q2 Of 2022
- Full data from Phase 2b CONTROL study presented at 2022 Winter Clinical Dermatology Conference -
- Company plans to initiate Phase 3 study in second quarter of 2022 -
BASKING RIDGE, NJ, Feb. 03, 2022 (GLOBE NEWSWIRE)